Quick Answer
Anebulo Pharmaceuticals, Inc. reported Operating Income Loss of -$9.22 million for the year ending 2025.
- Anebulo Pharmaceuticals, Inc. showed a decrease of -11.0% in Operating Income Loss from 2024 to 2025.
- This data is from Anebulo Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2020: -$324.6 thousand | Q1 2021: -$552.1 thousand | Q3 2021: -$1.55 million | Q4 2021: -$1.07 million | Q1 2022: -$1.88 million | Q3 2022: -$2.61 million | Q4 2022: -$3.81 million | Q1 2023: -$2.86 million | Q3 2023: -$2.54 million | Q4 2023: -$2.76 million | Q1 2024: -$1.66 million | Q3 2024: -$2.41 million | Q4 2024: -$2.59 million | Q1 2025: -$1.89 million | Q3 2025: -$2.26 million | Q4 2025: -$2.62 million.
- Over the full 5 years of available data (2021 to 2025), Anebulo Pharmaceuticals, Inc.'s Operating Income Loss has declined by 155.2%.
- Historical annual values: Fiscal year 2025: -$9.22 million | Fiscal year 2024: -$8.31 million | Fiscal year 2023: -$11.78 million | Fiscal year 2022: -$6.83 million | Fiscal year 2021: -$3.61 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: